{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:10:25Z","timestamp":1791421825213,"version":"4.3.3"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2005,9,11]],"date-time":"2005-09-11T00:00:00Z","timestamp":1126396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Dendritic cell (DC)-based therapy has proved to be effective in patients with a variety of malignancies. However, an optimal immunization protocol using DCs and the best means for delivering antigens has not yet been described. In this study, 20 patients with malignant melanoma in stages III or IV were vaccinated with autologous DCs pulsed with a melanoma cell lysate, alone (n\u2003=\u200313) or in combination with low doses of subcutaneous (s.c.) interleukin (IL)-2 injections (n\u2003=\u20037), to assess toxicity, immunological and clinical responses. Monocyte-derived DCs were morphological, phenotypic and functionally characterized in vitro. Peripheral blood mononuclear cells (PBMC), harvested from patients either prior to and after the treatment, were analysed using enzyme-linked immunosorbent spot (ELISPOT). After vaccination, 50% of the patients tested (seven of 13) from the first group and (three of seven) from the second, showed an increase in interferon (IFN)-\u03b3 production in response to allogeneic melanoma cell lines but not to controls. Four of five tested human leucocyte antigen (HLA)-A2+ patients with anti-melanoma activity also showed specific T cell responses against peptides derived from melanoma-associated antigens. Delayed type IV hypersensitivity reaction (DTH) against melanoma cell lysate was observed in six of 13 patients from the group treated with DC vaccines only and four of seven from the group treated with the combination of DCs and IL-2. Significant correlations were found between DTH-positive responses against tumour lysate and both disease stability and post-vaccination survival on the stage IV patients. There were no toxicities associated with the vaccines or evidence of autoimmunity including vitiligo. Furthermore, no significant enhancement was observed as a result of combining DC vaccination with IL-2. Our data suggest that autologous DCs pulsed with tumour lysate may provide a standardized and widely applicable source of melanoma specific antigens for clinical use. It is safe and causes no significant side effects and has been demonstrated to be partially efficient at triggering effective anti-melanoma immunity.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2005.02948.x","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T12:55:38Z","timestamp":1128603338000},"page":"555-568","source":"Crossref","is-referenced-by-count":86,"title":["Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients"],"prefix":"10.1093","volume":"142","author":[{"given":"A","family":"Escobar","sequence":"first","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"},{"name":"Blood Bank Service, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Serrano","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Blood Bank Service, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"},{"name":"Blood Bank Service, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Blood Bank Service, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Larrondo","sequence":"additional","affiliation":[{"name":"Blood Bank Service, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fodor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ferrada","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chile Clinical Hospital, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Salazar-Onfray","sequence":"additional","affiliation":[{"name":"Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,10,6]]},"reference":[{"key":"2022010711180265200_b1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol"},{"key":"2022010711180265200_b2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.1989.7.12.1863","article-title":"Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer","volume":"7","author":"Rosenberg","year":"1989","journal-title":"J Clin Oncol"},{"key":"2022010711180265200_b3","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"key":"2022010711180265200_b4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"2022010711180265200_b5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"2022010711180265200_b6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.182.1.255","article-title":"Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes","volume":"182","author":"Porgador","year":"1995","journal-title":"J Exp Med"},{"key":"2022010711180265200_b7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.183.1.317","article-title":"Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumour antigen in vivo","volume":"183","author":"Paglia","year":"1996","journal-title":"J Exp Med"},{"key":"2022010711180265200_b8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J Exp Med"},{"key":"2022010711180265200_b9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.186.8.1247","article-title":"Crystal dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumour immunity","volume":"186","author":"Song","year":"1997","journal-title":"J Exp Med"},{"key":"2022010711180265200_b10","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.4049\/jimmunol.160.9.4449","article-title":"Enhancement of tumour outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells","volume":"160","author":"Toes","year":"1998","journal-title":"J Immunol"},{"key":"2022010711180265200_b11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"2022010711180265200_b12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.4-2-140","article-title":"Clinical applications of dendritic cell cancer vaccines","volume":"4","author":"Baar","year":"1999","journal-title":"Oncologist"},{"key":"2022010711180265200_b13","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.4049\/jimmunol.165.6.3492","article-title":"Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells","volume":"165","author":"Schuler-Thurner","year":"2000","journal-title":"J Immunol"},{"key":"2022010711180265200_b14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00002371-200101000-00008","article-title":"Phase I trial intravenous peptide-pulsed dendritic cell as in patients with metastatic melanoma","volume":"24","author":"Lau","year":"2001","journal-title":"J Immunother"},{"key":"2022010711180265200_b15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J Exp Med"},{"key":"2022010711180265200_b16","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.4049\/jimmunol.172.7.3989","article-title":"Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells","volume":"172","author":"Koski","year":"2004","journal-title":"J Immunol"},{"key":"2022010711180265200_b17","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.4049\/jimmunol.171.11.5828","article-title":"The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumour immunity","volume":"171","author":"Watanabe","year":"2003","journal-title":"J Immunol"},{"key":"2022010711180265200_b18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00002371-200209000-00007","article-title":"Phenotypical and functional characterization of clinical grade dendritic cells","volume":"25","author":"De Vrics","year":"2002","journal-title":"J Immunother"},{"key":"2022010711180265200_b19","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J Exp Med"},{"key":"2022010711180265200_b20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1034\/j.1600-0463.2003.11107813.x","article-title":"Clinical application of dendritic cells in cancer vaccination therapy","volume":"111","author":"Svane","year":"2003","journal-title":"APMIS"},{"key":"2022010711180265200_b21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(02)00189-8","article-title":"Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories","volume":"268","author":"Berger","year":"2002","journal-title":"J Immunol Meth"},{"key":"2022010711180265200_b22","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.4049\/jimmunol.164.7.3600","article-title":"Large-scale culture and selective maturation of human Langerhans cells from granulocyte colony-stimulating factor-mobilized CD34+ progenitors","volume":"164","author":"Gatti","year":"2000","journal-title":"J Immunol"},{"key":"2022010711180265200_b23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor \u03b1","volume":"179","author":"Sallusto","year":"1994","journal-title":"J Exp Med"},{"key":"2022010711180265200_b24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"2022010711180265200_b25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1749-0774.2003.tb00151.x","article-title":"Dendritic cell-based combined immunotherapy with autologous tumour-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives","volume":"16","author":"Morisaki","year":"2003","journal-title":"Hum Cell"},{"key":"2022010711180265200_b26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1081\/CNV-120025091","article-title":"The first 1000 dendritic cell vaccines","volume":"21","author":"Ridgway","year":"2003","journal-title":"Cancer Invest"},{"key":"2022010711180265200_b27","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.6367046","article-title":"Biological activity of recombinant human interleukin-2 produced in Escherichia coli","volume":"22","author":"Rosenberg","year":"1984","journal-title":"Science"},{"key":"2022010711180265200_b28","first-page":"1997","article-title":"Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy","volume":"6","author":"Oelke","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2022010711180265200_b29","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.4049\/jimmunol.162.12.6959","article-title":"Cutting edge. rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma","volume":"162","author":"Dunbar","year":"1999","journal-title":"J Immunol"},{"key":"2022010711180265200_b30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"2022010711180265200_b31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.bjc.6600441","article-title":"Tissue distribution and differential expression of Melanocortin 1 Receptor, a malignant melanoma marker","volume":"87","author":"Salazar-Onfray","year":"2002","journal-title":"Br J Cancer"},{"key":"2022010711180265200_b32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2004.06.014","article-title":"CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions","volume":"21","author":"Ohl","year":"2004","journal-title":"Immunity"},{"key":"2022010711180265200_b33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.180.1.347","article-title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumour infiltrating lymphocytes","volume":"180","author":"Kawakami","year":"1994","journal-title":"J Exp Med"},{"key":"2022010711180265200_b34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/eji.1830240340","article-title":"Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes","volume":"24","author":"Wolfel","year":"1994","journal-title":"Eur J Immunol"},{"key":"2022010711180265200_b35","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","article-title":"Recognition of multiple epitopes in the human melanoma antigen gp100 by tumour-infiltrating T lymphocytes associated with in vivo tumour regression","volume":"154","author":"Kawakami","year":"1995","journal-title":"J Immunol"},{"key":"2022010711180265200_b36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/146532401753156377","article-title":"Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy","volume":"3","author":"Wong","year":"2001","journal-title":"Cytotherapy"},{"key":"2022010711180265200_b37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00262-002-0368-1","article-title":"Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation","volume":"52","author":"Spisek","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"2022010711180265200_b38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cyto.2003.08.012","article-title":"Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays","volume":"25","author":"Nagorsen","year":"2004","journal-title":"Cytokine"},{"key":"2022010711180265200_b39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1749-6632.1996.tb52660.x","article-title":"Interleukin-12 production by dendritic cells. The role of CD40\u2013CD40L interactions in Th1 T cell responses","volume":"795","author":"Kelsall","year":"1996","journal-title":"Ann NY Acad Sci"},{"key":"2022010711180265200_b40","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.4049\/jimmunol.166.7.4312","article-title":"Regulatory activity of autocrine IL-10 on dendritic cell functions","volume":"166","author":"Corinti","year":"2001","journal-title":"J Immunol"},{"key":"2022010711180265200_b41","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1128\/IAI.73.3.1590-1597.2005","article-title":"Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression","volume":"73","author":"Fedele","year":"2005","journal-title":"Infect Immun"},{"key":"2022010711180265200_b42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2567.2004.01978.x","article-title":"Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells","volume":"113","author":"Mehrotra","year":"2004","journal-title":"Immunology"},{"key":"2022010711180265200_b43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2567.2004.02076.x","article-title":"Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells","volume":"114","author":"Elkord","year":"2005","journal-title":"Immunology"},{"key":"2022010711180265200_b44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1567-5769(02)00267-9","article-title":"The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones","volume":"3","author":"Bradley","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"2022010711180265200_b45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-3083.2003.01238.x","article-title":"Monocyte-derived CD1a+ dendritic cells generated in two different culture systems: immunophenotypic and functional comparison","volume":"57","author":"Xia","year":"2003","journal-title":"Scand J Immunol"},{"key":"2022010711180265200_b46","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"2022010711180265200_b47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"2022010711180265200_b48","first-page":"4348","article-title":"Synthetic peptides derived from the melanocyte stimulating hormone receptor MC1R can stimulate HLA-A2 restricted CTL that recognize naturally processed peptides on human melanoma cells","volume":"57","author":"Salazar-Onfray","year":"1997","journal-title":"Cancer Res"},{"key":"2022010711180265200_b49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/scd.1.1997.6.253","article-title":"Efficient harvest of in vivo IL-2 activated CD3+ lymphocytes for adoptive immunotherapy by selective leukopheresis (lymphocytapheresis)","volume":"6","author":"Masucci","year":"1997","journal-title":"J Hematother"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2005.02948.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/3\/555\/42078484\/j.1365-2249.2005.02948.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/3\/555\/42078484\/j.1365-2249.2005.02948.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:26:07Z","timestamp":1683246367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/142\/3\/555\/6440418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,11]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,10,6]]},"published-print":{"date-parts":[[2005,9,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02948.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,9,11]]}}}